The development of a financial toxicity patient-reported outcome in cancer: The COST measure

Cancer

Volumn 120, Issue 20, 2014, Pages 3245-3253

  De Souza, Jonas A ^a   Yap, Bonnie J ^a   Hlubocky, Fay J ^a   Wroblewski, Kristen ^b   Ratain, Mark J ^a   Cella, David ^c   Daugherty, Christopher K ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Comparative effectiveness; Cost of cancer care; Outcomes research; Patient reported outcome; Quality of life

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; COLORECTAL CANCER; COMPREHENSIVE SCORE FOR FINANCIAL TOXICITY; CONTENT VALIDITY; CORRELATION COEFFICIENT; DEMOGRAPHY; ESOPHAGUS CANCER; FACE VALIDITY; FACTORIAL ANALYSIS; FEMALE; HEAD AND NECK CANCER; HEALTH ECONOMICS; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PATIENT ASSESSMENT; PATIENT REPORTED OUTCOME MEASURE; PILOT STUDY; PROSTATE CANCER; QUALITY OF LIFE; REDUNDANCY ANALYSIS; SCORING SYSTEM; THYROID CANCER; UTERINE CERVIX CANCER; VERY ELDERLY; ECONOMICS; MIDDLE AGED; NEOPLASMS; PSYCHOLOGY; QUESTIONNAIRE;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84908039974     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28814     Document Type: Article

References (57)

1. Stump TK, Eghan N, Egleston BL, et al. Cost concerns of patients with cancer. J Oncol Pract. 2013;9:251-257.
2. de Souza JA. The cost of cancer care: there is more than 1 elephant in the room. Oncology (Williston Park). 2012;26:926-928.
3. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18:381-390.
4. Zafar Y, Goetzinger AM, Fowler R, et al. Impact of out-of-pocket expenses on cancer care [abstract]. J Clin Oncol. 2011;29(15S). Abstract 6006.
5. Shankaran V, Jolly S, Blough D, Ramsey SD. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol. 2012; 30:1608-1614.
6. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011; 29:2534-2542.
7. Ubel PA, Abernethy AP, Zafar SY. Full disclosure - out-of-pocket costs as side effects. N Engl J Med. 2013;369:1484-1486.
8. Ratain MJ. Biomarkers and clinical care. Paper presented at: the American Association for the Advancement of Science/Food and Drug Law Institute (AAAS/FDLI) Colloquium, Personalized Medicine in an Era of Health Care Reform; October 26-27, 2009; Washington, DC. Available at: http://shr.aaas.org/projects/personalized- med/colloquia/ppts/Ratain.pdf. Accessed June 5, 2014.
9. Kaiser Family Foundation. What the actuarial values in the Affordable Care Act mean. Menlo Park, Calif; Kaiser Family Foundation; 2011. Available at: http://kaiserfamilyfoundation.files.wordpress.com/2013/01/8177.pdf. Accessed June 5, 2014.
10. National Public Radio. High-deductible health plans, gamble for some, on the rise: NPR News, July 28, 2013. Available at: http://www.npr.org/2013/07/28/206370593/high-deductible-health-plansgamble-for-some-on-the-rise. Accessed June 5, 2014.
11. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff. 2013;32:1143-1152.
12. Wong YN, Egleston BL, Sachdeva K, et al. Cancer patients' tradeoffs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care. 2013;51:838-845.
13. US Food and Drug Administration (FDA). Guidance for industry: patient-reported outcomes measures: use in medical product development to support labeling claims. Silver Spring, MD: FDA; 2009. Available at: http://www.fda.gov/downloads/drugs/guidancecomplian ceregulatoryinformation/guidances/ucm193282.pdf. Accessed June 5, 2014.
14. Cleeland CS, Sloan JA. Assessing the symptoms of cancer using patient-reported outcomes (ASCPRO): searching for standards. J Pain Symptom Manage. 2010;39:1077-1085.
15. Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 2013;369:397-400.
16. Wright JG, Feinstein AR. A comparative contrast of clinimetric and psychometric methods for constructing indexes and rating scales. J Clin Epidemiol. 1992;45:1201-1218.
17. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity - establishing and reporting the evidence in newly developed patientreported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2 - assessing respondent understanding. Value Health. 2011;14:978-988.
18. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity - establishing and reporting the evidence in newly developed patientreported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: part 1 - eliciting concepts for a new PRO instrument. Value Health. 2011;14:967-977.
19. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. CMAJ. 1986;134:889-895.
20. de KokM, Sixma HJ, van derWeijden T, et al. A patient-centred instrument for assessment of quality of breast cancer care: results of a pilot questionnaire [serial online]. Qual SafHealth Care. 2010;19:e40.
21. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199-220.
22. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
23. Briggs SR, Cheek JM. The role of factor analysis in the development and evaluation of personality scales. J Pers. 1986;54:106-148.
24. Clark LA, Watson D. Constructing validity: basic issues in objective scale development. Psychol Assess. 1995;7:309-319.
25. Mundfrom DJ, Shaw DG, Tian Lu K. Minimum sample size recommendations for conducting factor analyses. Int J Testing. 2005;5: 159-168.
26. Stevens J. Applied Multivariate Statistics for the Social Sciences. 5th ed. New York: Taylor & Francis Group; 2009.
27. Hair JF Jr, Black WC, Babin BJ. Multivariate Data Analysis. 7th ed. Upper Saddle River, NJ: Prentice Hall; 2009.
28. Fairclough DL, Cella DF. Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res. 1996;5:321-329.
29. Palattiyil G, Chakrabarti M. Coping strategies of families in HIV/AIDS care: some exploratory data from 2 developmental contexts. AIDS Care. 2008;20:881-885.
30. Joo S-H, Grable J. An exploratory framework of the determinants of financial satisfaction. J Fam Econ Issues. 2004;25:25-50.
31. Prawitz AD, Garman ET, Sorhaindo B, et al. In Charge Financial Distress/Financial Well-Being Scale: development, administration, and score interpretation. Financial Counsel Plan. 2006;17: 34-50.
32. Himmelstein DU, Thorne D, Warren E, et al. Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009;122:741-746.
33. Kaiser H. An index of factorial simplicity. Psychometrika. 1974;39: 31-36.
34. Bartlett MS. A note on multiplying factors for various chi square approximations. J R Stat Soc. 1954;16:296-298.
35. Walson C, Fitzsimmons V. Financial manager's perception of rural household economic well-being: development and testing of a composite measure. J Fam Econ Issues. 1993;14:193-214.
36. Rettig K, Leichtentritt R, Danes S. The effects of resources, decision making, and decision implementing on perceived family well-being in adjusting to an economic stressor. J Fam Econ Issues. 1999;20:5-34.
37. Tabachnick BG, Fidell LS. Using Multivariate Statistics. 3rd ed. New York: Harper Collins; 1996.
38. MacCallum RC, Widaman KF, Zhang S, et al. Sample size in factor analysis. Psychol Methods. 1999;4:84-99.
39. Danes SM, Rettig KD. The role of perception in the intention to change the family financial situation. J Fam Econ Issues. 1993;14: 365-389.
40. van den Hout WB, Goekoop-Ruiterman YPM, Allaart CF, et al. Cost-utility analysis of treatment strategies in patients with recentonset rheumatoid arthritis. Arthritis Rheum. 2009;61:291-299.
41. Freeman C, Carlson J, Sperry L. Adlerian marital therapy strategies with middle income couples facing financial stress. Am J Fam Ther. 1993;21:324-332.
42. van den Hout WB. Deficiencies in current evaluations of the costeffectiveness of biologic agents for RA. Nat Clin Pract Rheum. 2009; 5:78-79.
43. Drentea P. Age, debt and anxiety. J Health Soc Behav. 2000;41:437-450.
44. Mills RJ, Grasmick HG, Morgan CS, et al. The effects of gender, family satisfaction, and economic strain on psychological well-being. Fam Relat. 1992;41:440-445.
45. Voydanoff P. Economic distress and family relations: a review of the eighties. J Marriage Fam. 1990;52:1099-1115.
46. Voydanoff P. Economic distress and families: policy issues. J Fam Issues. 1984;5:273-288.
47. Bernard DM, Banthin JS, Encinosa WE. Health care expenditure burdens among adults with diabetes in 2001. Med Care. 2006;44: 210-215.
48. Selden TM, Banthin JS. Health care expenditure burdens among elderly adults: 1987 and 1996. Med Care. 2003;41:III-13-III-23.
49. Banthin JS, Bernard DM. Changes in financial burdens for health care. JAMA. 2006;296:2712-2719.
50. Banthin JS, Cunningham P, Bernard DM. Financial burden of health care, 2001-2004. Health Aff. 2008;27:188-195.
51. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York: Oxford University Press; 2005.
52. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30:4249-4255.
53. Beaton DE, Wright JG, Katz JN. Development of the QuickDASH: comparison of 3 item-reduction approaches. J Bone Joint Surg Am. 2005;87:1038-1046.
54. Oppenheim AN. Questionnaire Design, Interviewing and Attitude Measurement. London, United Kingdom: Pinter; 1992.
55. Bowling A. Research Methods in Health. Buckingham, United Kingdom: Open University Press; 1997.
56. Chen AY, DeSantis C, Jemal A. US mortality rates for oral cavity and pharyngeal cancer by educational attainment. Arch Otolaryngol. 2011;137:1094-1099.
57. Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007;99:1384-1394.